Actinium Pharmaceuticals Secures Canadian Patent Protection for Radiotherapy Programs in AML and Cell Therapy Conditioning
Key Insights
Actinium Pharmaceuticals received Canadian patent allowances for its Actimab-A (search) combination therapy in acute myeloid leukemia and Iomab-ACT conditioning program for gene-edited cell therapies.
The Canadian allowances expand protection across hematologic malignancies and next-generation conditioning approaches, building on existing patents in Japan and the United States.
These patents strengthen Actinium's global intellectual property estate of approximately 250 issued and pending patents, with the Canadian patents extending into 2038-2039.
Actinium Pharmaceuticals announced that the Canadian Intellectual Property Office has issued Notices of Allowance for two patent applications covering the company's Actimab-A (search) and Iomab-ACT programs. The allowances broaden Actinium's intellectual property protection across both hematologic malignancies and next-generation conditioning for gene-edited cell-based therapies in Canada, reinforcing a global patent estate of approximately 250 issued and pending patents and patent applications.
The Canadian allowances build on protection already secured in other major markets, including a previously granted Japanese patent for the Actimab-A (search) program and an issued U.S. patent for the Iomab-ACT program, with additional applications pending in the United States, Europe and China.
Actimab-A Combination Therapy for AML
The allowed Canadian application covers the use of Actimab-A (search) in combination with the CLAG-M (search) chemotherapy regimen for the treatment of acute myeloid leukemia. Actimab-A is one of Actinium's most advanced clinical-stage candidates and may serve as a therapeutic backbone for myeloid malignancies. The Canadian allowance complements a counterpart patent already granted in Japan, with applications pending in the United States and Europe.
The Canadian patent issuing from Application No. 3,087,346 titled "Combination Immunotherapy and Chemotherapy for the Treatment of a Hematological Malignancy" will have a patent term running into January 2039.
Iomab-ACT for Gene-Edited Cell Therapies
The second allowed application covers Actinium's targeted CD45 (search) conditioning approach used to prepare patients for gene-edited cell-based therapies. Iomab-ACT is designed as a targeted conditioning agent intended to enable adoptive cell therapies. The Canadian allowance builds on a patent already granted in the United States, with additional applications pending in the United States, Europe and China.
The Canadian patent issuing from Application No. 3,078,963 titled "Anti-CD45 (search)-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell-Based Therapies" will have a patent term running into October 2038.
Strategic Intellectual Property Protection
"These two allowances reflect the breadth and depth of the innovation across our radiotherapy platform and our commitment to protecting it in every key market," said Adeela Kamal, Ph.D., EVP-R&D of Actinium Pharmaceuticals. "Securing coverage for both our Actimab-A (search) CLAG-M (search) combination in AML and our Iomab-ACT conditioning approach for gene-edited cell-based therapies underscores the strength of our science and the durability of the franchises we are building."
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its pipeline reflects this strategy across three areas: solid tumor therapeutics including ATNM-400 (search) and Actimab-A (search) with pan-tumor potential; Actimab-A as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in collaboration with the National Cancer Institute; and targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for adoptive cell therapy conditioning.